Comprehensive clinical sequencing programs for cancer patients have been initiated at several medical centers, including our own [1] [2] [3] . In addition to the potential for identifying actionable therapeutic targets in cancer patients, these clinical sequencing efforts may lead to the identification of novel driver mutations that might be relatively rare in a common cancer types or newly found in relatively rare cancer types. In this study, an individual with cellular solitary fibrous tumor/hemangiopericytoma (SFT/HPC) was enrolled in our clinical sequencing project called MI-ONCOSEQ (the Michigan Oncology Sequencing Program). SFT represents a wide spectrum of tumor types of mesenchymal origin that can affect virtually any region of the body 4 . SFT is composed of CD34-positive fibroblastic-appearing cells arranged in a distinctive patternless growth of alternating cellularity and collagenous stroma. Whereas most SFTs are benign and can be cured with surgery, 15-20% of affected individuals with SFT progress, with either local recurrence or distant metastases, which can be difficult to treat 4,5 . It is unclear whether SFTs originating at diverse sites, such as the meninges, lung and breast, share a common pathogenesis.
l e t t e r s Comprehensive clinical sequencing programs for cancer patients have been initiated at several medical centers, including our own [1] [2] [3] . In addition to the potential for identifying actionable therapeutic targets in cancer patients, these clinical sequencing efforts may lead to the identification of novel driver mutations that might be relatively rare in a common cancer types or newly found in relatively rare cancer types. In this study, an individual with cellular solitary fibrous tumor/hemangiopericytoma (SFT/HPC) was enrolled in our clinical sequencing project called MI-ONCOSEQ (the Michigan Oncology Sequencing Program). SFT represents a wide spectrum of tumor types of mesenchymal origin that can affect virtually any region of the body 4 . SFT is composed of CD34-positive fibroblastic-appearing cells arranged in a distinctive patternless growth of alternating cellularity and collagenous stroma. Whereas most SFTs are benign and can be cured with surgery, 15-20% of affected individuals with SFT progress, with either local recurrence or distant metastases, which can be difficult to treat 4, 5 . It is unclear whether SFTs originating at diverse sites, such as the meninges, lung and breast, share a common pathogenesis.
The index subject was a 44-year-old woman who had surgery and post-operative radiation for an anaplastic meningioma in 2002. Later review reclassified this tumor as a meningeal malignant SFT. In 2009, magnetic resonance imaging (MRI) showed a new brain mass and a paraspinal mass. Laminectomy was performed, and review of the tissue showed metastatic SFT, which was strongly immunoreactive for CD34. In 2011, the patient was enrolled in the MI-ONCOSEQ integrated cancer sequencing program ( Supplementary Fig. 1a ) after progression of sarcoma while on chemotherapy. Computed tomography (CT)-guided core needle biopsies were obtained from a metastatic site in the liver (Fig. 1a) . The specimen showed the typical morphological features of SFT with HPC-like vessels, collagenous stroma and patternless architecture of spindled-to-ovoid tumor cells (Fig. 1b,c) .
Immunostaining for CD34 was positive in the tumor cells and in endothelial cells, highlighting branching vessels (Fig. 1d) . The biopsy cores used for molecular analysis had over 70% tumor cell content according to morphological analysis.
High-quality DNA and RNA were isolated from the core needle biopsies and subjected to next-generation sequencing. Whole-exome sequencing of the tumor and matched normal tissue from MO_1005 identified 14 nonsynonymous point mutations (Supplementary Table 1 ). No significant germline aberrations or somatic point mutations were identified in genes frequently mutated in cancer, such as TP53, KRAS, BRAF and PIK3CA, among others. The exome Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing data coupled with single-nucleotide variant (SNV) candidate modeling was used to estimate the tumor content of the biopsy specimen at 70%, corroborating the histological assessment (Supplementary Fig. 2) . A global landscape of somatic copy-number alterations was generated from exome sequencing data (Fig. 1e) , and there were only a few regions of substantial copy-number gain or loss (Supplementary Tables 2  and 3) . A focal 56-kb one-copy deletion was observed in the STAT6 locus ( Fig. 1e and Supplementary Fig. 3) . Notably, paired-end transcriptome sequencing of RNA identified an intrachromosomal fusion between NAB2 and STAT6 (Fig. 1f) . The NAB2-STAT6 fusion was represented by 1,104 paired-end reads either spanning or encompassing the fusion junction of exon 6 of NAB2 to exon 18 of STAT6. In the normal genome, NAB2 and STAT6 are adjacent genes on chromosome 12q13 that are transcribed in opposite directions.
Using primers within exon 6 of NAB2 and exon 19 of STAT6, we confirmed the NAB2-STAT6 fusion in the index case by RT-PCR followed by Sanger sequencing of the amplified product (Fig. 2a) . To confirm that the fusion resulted from a DNA-level rearrangement, we carried out long-range PCR of genomic DNA. A 1.3-kb product was obtained specifically in the tumor from the index subject and not in the matched normal tissue (Fig. 2b, left) . This allowed us to specifically map the genomic breakpoint of the NAB2-STAT6 fusion (Fig. 2b, right) and confirmed that a genomic inversion occurred at the 12q13 locus, fusing NAB2 and STAT6 in a common direction of transcription.
To determine whether the NAB2-STAT6 fusion was recurrent, we interrogated 51 cases of SFT, malignant and benign, from a range of anatomical sites ( Table 1 and Supplementary Fig. 1b) l e t t e r s npg l e t t e r s a total of 27 cases of SFT by transcriptome sequencing. All 27 cases showed high levels of a NAB2-STAT6 gene fusion, with some variation in the precise exon structure of the fusions ( Table 1 and  Supplementary Table 4 ). The number of paired-end reads spanning or encompassing the fusion ranged from 25 to 4,483 per case. In each case, exon 2, 4, 6 or 7 of NAB2 was fused in frame to exon 2, 3, 5, 6, 17 or 18 of STAT6. Most of the transcript fusions were at defined exon boundaries, but a small set had fusion junctions within exons ( Table 1) . Representative fusions are shown in Figure 2c . SFT-3 is an example of a complex fusion, with a 72-bp fragment derived from the 3′ UTR of NAB2 and intron 16 of STAT6 at the fusion junction, retaining the reading frame. RT-PCR combined with capillary sequencing was carried out on an additional 24 cases of SFT from the Memorial Sloan-Kettering Cancer Center (MSKCC), and all cases were also Fig. 3 ). The reciprocal transcripts varied by case, ranging from exact STAT6-NAB2 reciprocals to shorter variants missing one to several STAT6 exons, both in and out of frame. NAB2 comprises an N-terminal EGR1-binding domain (EBD), a NAB conserved region 2 (NCD2) and a C-terminal transcriptional repressor domain (RD). STAT6 comprises a DNA-binding domain (DBD), SH2 domain and a C-terminal transcriptional activation domain (TAD). The domain structures of the wild-type NAB2 and STAT6 proteins as well as of six representative NAB2-STAT6 fusion proteins identified by transcriptome sequencing in this study are shown (Fig. 3a) . A common feature of all of the NAB2-STAT6 fusion proteins was variable truncation in the RD motif of NAB2, which was minimally fused to the TAD motif of STAT6.
Expression of the predicted NAB2-STAT6 fusion protein products was confirmed by immunoblot analysis of three cases of SFT (Fig. 3b) . An antibody to the C terminus of STAT6, present in all fusions, detected the respective fusion proteins only in the tumor samples, whereas matched normal tissues expressed only wild-type STAT6.
SFT-10 and SFT-44 had a common fusion variant, whereas SFT-14 had a larger variant similar to that in SFT-31 (Fig. 3a) . Similarly, immunofluorescence using this antibody to the C terminus of STAT6 showed strong nuclear staining (Fig. 3c) . Immunofluorescence using an antibody to STAT6 phosphorylated at Tyr641 showed a complete absence of phosphorylation in the eight SFTs tested, whereas nuclear staining was evident in the entrapped endothelial cells or adjacent lung parenchyma (Supplementary Fig. 6 ). This pattern of C-terminal STAT6 nuclear staining and absence of nuclear phosphorylated STAT6 in SFTs is consistent with the NAB2-STAT6 fusion protein rather than activated wild-type STAT6.
The NAB2-STAT6 fusion allele from the index case (MO_1005) was cloned into a lentiviral vector with a sequence encoding a Flag epitope tag. Benign prostate RWPE-1 cells were infected with control virus (empty vector) or with virus encoding NAB2-STAT6, and pooled stable cell lines were generated. Stable cell lines expressing high and low levels of NAB2-STAT6 were characterized (Fig. 3d) . Notably, the cell line with high NAB2-STAT6 expression showed markedly increased proliferation compared to the cells transduced with control virus, whereas the cell line with low NAB2-STAT6 expression showed an intermediate level of proliferation (Fig. 3e) . The proliferation of both NAB2-STAT6-expressing cell lines could be inhibited by small interfering RNA (siRNA) knockdown of EGR1 expression, whereas the cell line transduced with control virus was unaffected (Supplementary Fig. 7) . As wild-type NAB2 is a well-characterized repressor of EGR1 transcriptional activity 6,7 , we measured the expression of established EGR1 target genes in the cell lines stably expressing NAB2-STAT6 (Fig. 3f) 8 . In contrast to the known activity of NAB2, the NAB2-STAT6 fusion induced expression of EGR1 target genes. This was further verified using an EGR1 response element reporter assay (Fig. 4a) . Expression of EGR1 induced expression of the reporter gene by over 200-fold compared to vector control. This induction could be repressed over 90% by coexpression of wild-type NAB2 repressor. npg l e t t e r s Expression of the NAB2-STAT6 fusion resulted in the opposite effect. Expression was elevated tenfold over that seen with EGR1 alone, confirming that the fusion protein functions as an activator of EGR1-targeted transcription. No significant effect was seen in parallel experiments using a STAT6 response element reporter, showing that the NAB2-STAT6 fusion functions through EGR1 target genes rather than STAT6 target genes. The interaction of the NAB2-STAT6 fusion with EGR1 was further confirmed by chromatin immunoprecipitation (ChIP)-PCR of known EGR1 target gene promoters in cells transiently expressing Flag-tagged NAB2-STAT6 (Fig. 4b) . Cells receiving vector control showed no specific enrichment, whereas the NAB2-STAT6 fusion showed specific enrichment for the binding of known EGR1-responsive sites and not for negative control sites. Furthermore, the physical interaction of the NAB2-STAT6 fusion protein with EGR1 was demonstrated by coimmunoprecipitation (Supplementary Fig. 8) .
To investigate the role of the NAB2-STAT6 fusion in determining the transcriptional pattern of SFT, we curated a robust set of EGR1 target genes from an EGR1 ChIP-seq experiment in human myelogenous leukemia K562 cells (GSM803414) 9 . We extracted the sets of highly enriched peaks from this data set (at 5%, 10% and 25% percentiles) and performed initial analysis of these peaks using the GREAT bioinformatics tool 10 . For example, the EGR1-responsive peaks with scores in the top 5% (918 peaks) were mapped to 1,222 genes (some peaks mapped to more than 1 gene), and these 1,222 genes were highly enriched for known EGR DNA-binding motifs (Supplementary Fig. 9 ). To assess whether SFT gene expression profiles were enriched for this set of EGR1 target genes, we used Affymetrix U133A microarray data from 23 SFTs and 34 non-SFT soft-tissue sarcomas spanning 7 subtypes 11 . We then compared the gene expression profiles of SFT versus non-SFT sarcomas across our EGR1 target gene lists using gene set enrichment analysis (GSEA) 12 . Indeed, we observed a positive and highly significant enrichment of the expression of EGR1 target genes in SFT compared to non-SFT sarcomas (Supplementary Fig. 10 ). The list of EGR1 target genes in the top 5% was the most highly enriched in SFT tumors (enrichment score (ES) = 0.35, P value < 0.001, false discovery rate (FDR) q value = 0.025, family-wise error rate (FWER) P value = 0.006). Overall, the set of genes differentially expressed in SFT and other sarcomas was significantly enriched for EGR1 target genes. RNA-seq analysis of 7 SFTs compared with 282 other tumor samples also showed high-level expression of EGR1 target genes. We found that EGR1 target genes, including NAB2, NAB1, IGF2, FGF2, PDGFD, and receptor tyrosine kinases, such as FGFR1 and NTRK1, all had outlier expression levels in SFTs relative to other tumor types ( Fig. 4c and 
Supplementary Tables 5 and 6).
Recurrence analysis on an independent set of tumor samples suggested that nearly all SFTs (100% in this study) harbor a NAB2-STAT6 fusion. This would suggest that the NAB2-STAT6 gene fusion is pathognomonic for SFT and that the spectra of SFT characteristics and morphology have a common genetic origin. Assessment of NAB2-STAT6 fusion status could be used as a genetic marker in sarcoma cases that are not unambiguously classified as SFT (for example, cases of CD34-negative SFT and malignant and dedifferentiated SFT) 13 . Although the structure of the fusion proteins varies in individual SFT cases, all fusion proteins have a truncation of the transcriptional repressor domain of NAB2 with an in-frame fusion to the transcriptional activation domain of STAT6 (although additional STAT6 domains may be included). The truncation of the repressor domain of NAB2 attenuates its repressive activity, while addition of a strong, intact activation domain engenders transcriptional activation potential.
How does the NAB2-STAT6 fusion potentially explain neoplastic progression in SFT? NAB2 is a well-known coregulator of EGR transcription factors 7 , and all of the fusion proteins identified in SFT maintain an intact N-terminal EBD. EGR1 is a zinc-finger transcription factor that couples growth factor signaling with the induction of nuclear programs of differentiation and proliferation, which are mediated by EGR1 target genes (Fig. 4d) 14 . As part of a homeostatic loop, NAB2 is induced by EGR family members and npg l e t t e r s functions in a negative feedback manner to repress their activity 15, 16 . In the context of SFT, the NAB2 fusion gains an activation domain from the signaling molecule STAT6, which converts a transcriptional repressor (NAB2) into a potent transcriptional activator (NAB2-STAT6) of EGR1. This leads to constitutive activation of EGRmediated transcription, culminating in a feedforward loop that drives neoplastic progression. We found that EGR target genes, including NAB2, NAB1, IGF2, FGF2, PDGFD, and receptor tyrosine kinases, such as FGFR1 and NTRK1, all exhibited outlier expression levels in SFTs relative to other tumor types (Fig. 4c) . Furthermore, a number of kinases, including FGFR1, are targets of EGR1 and are also overexpressed in SFT, which may be explained by the feedforward loop potentiated by the NAB2-STAT6 fusion. Although it will be a challenge to target the NAB2-STAT6 fusion protein therapeutically, some of the downstream kinases it induces may serve as attractive drug targets that should be evaluated in clinical trials for SFT. A clinical study that tested the kinase inhibitor sunitinib and the figitumimab antibody to IGF1R in SFT showed some positive responses 17 . Taken together, the data in this study implicate aberrations in NAB2 and STAT6 in the neoplastic pathways of virtually all SFTs, both benign and malignant, and may predict a role for these genes in other more common tumor types, as cancer genome sequencing efforts continue. Integrative sequencing provides a molecular definition of cancers to supplement and clarify histopathological characterizations 18 . In addition to suggesting actionable mutations, unbiased clinical sequencing efforts may shed light on the biology of rare cancers or individual cases of more common cancer types. To our knowledge, this is one of the first examples of how a gene fusion can convert a transcriptional repressor (NAB2) into a transcriptional activator (NAB2-STAT6) of mitogenic pathways that can be subverted during neoplastic progression.
METhOdS
Methods and any associated references are available in the online version of the paper.
Accession codes. The exome and transcriptome sequencing data have been deposited in the database of Genotypes and Phenotypes (dbGaP) under accession phs000567.v1.p1.
Note: Supplementary information is available in the online version of the paper.

ONLINE METhOdS
Clinical study. Research was performed under institutional review board (IRB)-approved studies. Patients are enrolled and consented through a University of Michigan IRB-approved protocol for integrative tumor sequencing, MI-ONCOSEQ (Michigan Oncology Sequencing Protocol, IRB HUM00046018) 1 . Medically fit patients 18 years or older with advanced or refractory cancer were eligible for the study. Informed consent detailed the risks of integrative sequencing and included up-front genetic counseling. Biopsies were arranged for safely accessible tumor sites. Needle biopsies were snap frozen in optimal cutting temperature (OCT) compound, and a longitudinal section was cut. Hematoxylin and eosin-stained frozen sections were reviewed by the study pathologist to identify the cores with the highest tumor content. Remaining portions of each needle biopsy core were retained for nucleic acid extraction.
Thirty SFTs with available frozen tissue material from MSKCC files were included for analysis. Seventeen of the SFTs were previously analyzed as part of a gene expression profiling study, and CEL files have been made publicly available 11 . There were 16 females and 14 males with a wide age range at diagnosis (12-79 years, mean 52 years). The retrospective validation study was approved by the appropriate IRB (IRB 02-060).
DNA and RNA isolation and cDNA synthesis. Genomic DNA from frozen needle biopsies and blood was isolated using the Qiagen DNeasy Blood & Tissue kit according to the manufacturer's instructions. Total RNA was extracted from frozen needle biopsies (for RNA-seq libraries, gene expression analysis and RT-PCR) using the Qiazol reagent with disruption using a 5-mm bead on a TissueLyser II (Qiagen). RNA was purified using a miRNeasy kit (Qiagen) according to the manufacturer's instructions. cDNA was synthesized from total RNA using SuperScript III (Invitrogen) and random primers (Invitrogen). For the MSKCC samples, total RNA was extracted from frozen tumor tissue using TRIzol reagent according to the manufacturer's instructions (Invitrogen).
Next-generation sequencing library preparation. Exome libraries of matched pairs of tumor-normal genomic DNA were generated using the Illumina TruSeq DNA Sample Prep kit, following the manufacturer's instructions. RNA-seq transcriptome libraries were prepared following Illumina's TruSeq RNA protocol, using 2 µg of total RNA. PolyA+ RNA was isolated using SeraMag oligo(dT) beads (Thermo Scientific) and fragmented with the Ambion Fragmentation Reagents kit. cDNA synthesis, end repair, A-base addition and ligation of the Illumina-indexed adaptors were performed according to Illumina's protocol. Libraries were then size selected for cDNA fragments of 250-300 bp on a 3% Nusieve 3:1 (Lonza) agarose gel, recovered using QIAEX II gel extraction reagents (Qiagen) and PCR amplified using Phusion DNA polymerase (NEB) for 14 PCR cycles. Paired-end libraries were sequenced with the Illumina HiSeq 2000 (2 × 100-nt read length). Reads that passed the chastity filter of Illumina BaseCall software were used for subsequent analysis. Summary sequencing statistics are presented in Supplementary Table 7 .
We used the publicly available software FastQC to assess sequence quality. For each lane, we examined per-base quality scores across the length of the reads. Lanes were deemed passing if the per-base quality score box plot indicated that >75% of the reads had >Q20 for bases 1-80. All lanes passed this threshold. In addition to raw sequence quality, we also assessed alignment quality using the Picard package.
Mutation analyses. We annotated the resulting somatic mutations using RefSeq transcripts. Human Genome Organization (HUGO) gene names were used. For NAB2 mRNA and protein, positions and annotations were derived from RefSeq accessions NM_005967 and NP_005958, respectively. For STAT6 mRNA and protein, positions and annotations were derived from RefSeq accessions NM_001178078 and NP_001171549, respectively. The impact of coding nonsynonymous amino-acid substitutions on the structure and function of a protein was assessed using PolyPhen-267. We also assessed whether the somatic variant was previously reported in dbSNP135 or the Catalogue of Somatic Mutations in Cancer (COSMIC) v5668.
Copy-number aberrations were quantified and reported for each gene as the segmented normalized log 2 -transformed exon coverage ratios between each tumor sample and its matched normal sample 19 . To account for observed associations between coverage ratios and variation in GC content across the genome, lowess normalization was used to correct per-exon coverage ratios before segmentation analysis. Specifically, mean GC percentage was computed for each targeted region, and a lowess curve was fit to the scatter plot of log 2 coverage ratios versus mean GC content across the targeted exome using the lowess function in R (version 2.13.1) with smoothing parameter f = 0.05.
Somatic point mutations were identified in the tumor exome sequence data using the matched normal exome data to eliminate germline polymorphisms. Parameters and computational methods were as previously described 20 .
To identify gene fusions, paired-end transcriptome reads passing filter were mapped to the human reference genome (hg19) and UCSC genes, allowing up to two mismatches, with Illumina ELAND software and Bowtie 21 . Sequence alignments were subsequently processed to nominate gene fusions using previously described methods 22, 23 . In brief, paired-end reads were processed to identify any that either contained or spanned a fusion junction. Encompassing paired reads referred to those in which each read aligned to an independent transcript, thereby encompassing the fusion junction. Spanning paired reads referred to those in which one sequence read aligned to a gene and its pairedend sequence spanned the fusion junction. Both categories of reads underwent a series of filtering steps to remove false positives before being merged together to generate the final nominations of chimera. Reads supporting each fusion were realigned using BLAT (UCSC Genome Browser) to reconfirm the fusion breakpoint.
For RNA-seq gene expression analysis, transcriptome data were processed as previously described 1 . Table 8 ). PCR products were analyzed by agarose gel electrophoresis. Amplified PCR products were gel purified and then sequenced using the Sanger method. qRT-PCR assays were performed using SYBR Green Master Mix (Applied Biosystems) and were carried out with the StepOne Real-Time PCR System (Applied Biosystems). Relative mRNA levels of the fusion transcripts were normalized to the expression of the housekeeping gene GAPDH. Oligonucleotide primers were obtained from Integrated DNA Technologies (IDT; sequences given in Supplementary  Table 8 ). To detect the genomic fusion junction between the NAB2 and STAT6 genes in MO_1005 tumor DNA, primers were designed flanking the predicted genomic junction, and PCR was carried out to amplify the fusion fragments. PCR products were purified from agarose gels using the QIAEX II system and sequenced by Sanger sequencing.
RT-PCR, qRT-PCR
Using similar conditions, RT-PCR for the detection of STAT6-NAB2 reciprocal transcripts was performed on all 30 SFT cases, and, depending on the expected fusion transcript, 2 primer pairs were used: STAT6 Ex13F and NAB2 Ex7R or STAT6 Ex1F and NAB2 Ex7R (Supplementary Table 8 ).
Immunoblot and immunofluorescence assays. Total protein lysates were extracted from frozen tissue from eight SFTs. In three of the cases, frozen normal tissues of adequate quality were available for protein extraction for comparison. Electrophoresis and immunoblotting were performed using 30 µg of total protein extract, following standard protocols. Total STAT6 and β-actin were detected by rabbit polyclonal antibody to STAT6 (Cell Signaling Technology, 9362S; 1:1,500 dilution) and rabbit monoclonal antibody to β-actin (Cell Signaling Technology, 4970; 1:1,500 dilution). The secondary antibody used was goat antibody to rabbit (Santa Cruz Biotechnology, sc-2034) at a 1:20,000 dilution. The same antibody to total STAT6 was used for immunofluorescence to detect cellular localization. Immunofluorescence to detect phosphorylated STAT6 was performed using the P-STAT6 Y641 primary antibody from Cell Signaling (9361; 1:100 dilution) and an Alexa Fluor 594-conjugated secondary goat antibody to rabbit IgG from Invitrogen (A11037; 4 µg/ml).
NAB2-STAT6
cloning, expression and stable cell line analyses. The NAB2-STAT6 fusion allele was PCR amplified from the cDNA of the index case npg (MO_1005) using the primers listed in Supplementary Table 8 and the Expand High-Fidelity protocol (Roche). The PCR product was digested with the restriction endonuclease CpoI (Fermentas) and ligated into the pCDH510B lentiviral vector (System Biosciences), which had been modified to contain a sequence encoding an N-terminal Flag epitope tag. Lentiviruses were produced by cotransfecting the NAB2-STAT6 construct or empty vector with the ViraPower packaging mix (Invitrogen) into 293T cells using FuGENE HD transfection reagent (Roche). After 36 h, viral supernatants were harvested, centrifuged at 5,000 g for 30 min and filtered through a 0.45-micron Steriflip filter unit (Millipore). Benign RWPE-1 cells at 30% confluence were infected at a multiplicity of infection (MOI) of 20, with the addition of polybrene at 8 µg/ml. After 48 h, cells were split and placed into selective medium containing 10 µg/ml puromycin. Two stable pools of resistant cells were obtained and analyzed for the expression of Flag-NAB2-STAT6 by protein blot analysis with monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, F1804). Expression was confirmed by qPCR for the NAB2-STAT6 fusion allele.
For cell proliferation assays, cells expressing control empty vector or low or high levels of NAB2-STAT6 were plated in quadruplicate at 8,000 cells per well in 24-well plates. Plates were incubated at 37 °C in a 5% CO 2 atmosphere using the IncuCyte live-cell imaging system (Essen Biosciences). Cell proliferation was assessed by kinetic imaging confluence measurements at 3-h intervals.
ChIP-PCR assays. We grew 293T cells to 70-80% confluence in DMEM supplemented with 10% FBS. Cells were then transfected with a construct expressing EGR1-Myc alone or cotransfected with constructs expressing EGR1-Myc and Flag-NAB2-STAT6 using FuGENE 6 reagent. After 24 h, cells were cross-linked with 1% formaldehyde, neutralized with 0.125 M glycine, rinsed twice with ice-cold PBS and pelleted by centrifugation. ChIP-seq was performed as previously described 24 .
Coimmunoprecipitation of EGR1 and NAB2-STAT6. We grew 293T cells to ~70% confluence in DMEM supplemented with 10% FBS, and cells were transfected with construct expressing Myc-tagged EGR1 alone or cotransfected with constructs expressing EGR1-Myc and Flag-tagged NAB2-STAT6 using FuGENE 6 reagent. After 24 h, cells were cross-linked with 1% formaldehyde, neutralized with 0.125 M glycine, rinsed twice with ice-cold PBS and pelleted by centrifugation. Cell pellets were lysed in lysis buffer, and immunoprecipitation was carried out with antibody to the Myc tag (Sigma, M5546) and protein G Dynabeads (Invitrogen). Precipitates were washed three times with IP Wash buffer (100 mM Tris, pH 8.0, 200 mM LiCl, 1% NP-40 and 1% sodium deoxycholate), resuspended in 3× SDS-PAGE loading buffer and incubated at 95 °C for 20 min to reverse cross-linking. Flag-NAB2-STAT6 fusion protein was detected by protein blotting with antibody to Flag (Sigma).
siRNA knockdown of EGR1. RWPE-1 stable cell lines (with vector control or high or low expression of NAB2-STAT6) were transfected twice with EGR1-targeting siRNA or non-targeting siRNA (Thermo Scientific Dharmacon) using Oligofectamine (Invitrogen). The siRNAs used were as follows: ON-TARGETplus EGR1 LQ-006526-00-0002 and ON-TARGETplus Nontargeting pool. After 24 h, cells were trypsinized and plated in quadruplicate at 4,000 cells per well in 24-well plates. Plates were incubated at 37 °C in a 5% CO 2 atmosphere in the IncuCyte live-cell imaging system. Cell proliferation rates were assessed by kinetic imaging confluence measurements at 3-h intervals.
Luciferase assays. We seeded 293T cells into 12-well dishes in triplicate and allowed them to attach overnight. Cells were serum starved for 12 h and transfected with different combinations of constructs encoding EGR1 (Origene), wild-type NAB2 (Origene) and NAB2-STAT6 fusion along with a mixture of EGR1-responsive firefly luciferase construct and constitutively expressed Renilla luciferase construct (SABiosciences). After 24 h, cell lysates were prepared and measured for EGR1 activity using Promega Dual Luciferase reagents and Passive Lysis Buffer. Firefly luciferase levels were normalized using corresponding Renilla luciferase levels for each condition. To test whether the NAB2-STAT6 fusion protein functions through the STAT6 signaling pathway, a STAT6-responsive firefly luciferase reporter was constructed in pGL4.10 (Promega), and luciferase activity assays were performed. The sequences of the oligonucleotides used for the preparation of the STAT6-responsive firefly luciferase construct are given in Supplementary Table 8. 
